Carisma Therapeutics (NASDAQ:CARM) Price Target Cut to $1.00 by Analysts at D. Boral Capital

Carisma Therapeutics (NASDAQ:CARM) had its price target reduced by equities research analysts at D. Boral Capital from $12.00 to $1.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. D. Boral Capital’s target price indicates a potential upside of 222.58% from the stock’s previous close.

CARM has been the topic of several other reports. BTIG Research cut Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 10th. Evercore ISI reaffirmed an “in-line” rating and issued a $0.70 price objective (down from $4.00) on shares of Carisma Therapeutics in a report on Wednesday, December 11th. Baird R W lowered shares of Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. HC Wainwright reaffirmed a “neutral” rating on shares of Carisma Therapeutics in a report on Monday, December 16th. Finally, Robert W. Baird downgraded shares of Carisma Therapeutics from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $10.00 to $1.00 in a report on Thursday, December 12th. Five investment analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Carisma Therapeutics has a consensus rating of “Hold” and an average price target of $2.74.

Carisma Therapeutics Stock Performance

Shares of CARM stock opened at $0.31 on Tuesday. Carisma Therapeutics has a one year low of $0.31 and a one year high of $2.30. The business’s 50 day simple moving average is $0.44 and its 200 day simple moving average is $0.66. The stock has a market capitalization of $12.94 million, a PE ratio of -0.20 and a beta of 1.55. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.23 and a quick ratio of 3.23.

Institutional Trading of Carisma Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Wexford Capital LP boosted its holdings in shares of Carisma Therapeutics by 75.5% in the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after purchasing an additional 15,000 shares during the period. Renaissance Technologies LLC raised its position in Carisma Therapeutics by 11.9% during the 4th quarter. Renaissance Technologies LLC now owns 231,357 shares of the company’s stock valued at $97,000 after purchasing an additional 24,600 shares in the last quarter. Finally, Barclays PLC lifted its holdings in shares of Carisma Therapeutics by 3,661,933.3% in the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after buying an additional 549,290 shares during the period. Institutional investors own 44.27% of the company’s stock.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.